Table 2 Baseline patient characteristics are shown for the full dataset and by the duration of response (DoR <versus ≥12 months)

From: Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

Characteristics

G3 NENs

DoR < 12 m

DoR ≥ 12 m

N = 37

N = 32

N = 5

Age, years

Median (range)

61 (28–84)

61 (28–84)

60 (44–80)

Gender, n (%)

Male

25 (67.6)

22 (68.8)

3 (60.0)

Female

12 (32.4)

10 (31.2)

2 (40.0)

ECOG PS, n (%)

0

11 (29.7)

10 (31.2)

1 (20.0)

1

22 (59.5)

18 (56.2)

4 (80.0)

2

4 (10.8)

4 (12.5)

0 (0.0)

Stage at diagnosis, n (%)

I

1 (2.7)

1 (3.1)

0 (0.0)

III

1 (2.7)

0 (0.0)

1 (20.0)

IV

35 (94.6)

31 (96.9)

4 (80.0)

Differentiation, n (%)

NET

12 (32.4)

11 (34.4)

1 (20.0)

NEC

25 (67.6)

21 (65.6)

4 (80.0)

Ki 67, n (%)

21 – 55%

12 (32.4)

11 (34.4)

1 (20.0)

>55%

25 (67.6)

21 (65.6)

4 (80.0)

Primary site, n (%)

Esophageal

2 (5.4)

2 (6.2)

0 (0.0)

Gastric

6 (16.2)

4 (12.5)

2 (40.0)

Pancreatic

15 (40.5)

13 (40.6)

2 (40.0)

Colonic

4 (10.8)

4 (12.5)

0 (0.0)

Rectal

2 (5.4)

2 (6.2)

0 (0.0)

Small intestine

2 (5.3)

1 (3.1)

1 (20.0)

Unknown

61 (16.2)

6 (18.8)

0 (0.0)

Metastatic sites number, n (%)

1

10 (27.0)

8 (25.0)

2 (40.0)

≥2

27 (73.0)

24 (75.0)

3 (60.0)

Metastasis sites, n (%)

Liver

31 (83.8)

29 (90.6)

2 (40.0)

Lung

9 (24.3)

9 (28.1)

0 (0.0)

Lymph nodes

18 (48.6)

15 (46.9)

3 (60.0)

Bone

10 (27.0)

10 (31.2)

0 (0.0)

Previous surgery, n (%)

Yes

6 (16.2)

4 (12.5)

2 (40.0)

No

30 (81.1)

27 (84.4)

3 (60.0)

Unknown

1 (2.7)

1 (3.1)

0 (0.0)

CgA, n (%)

<2x ULN

7 (18.9)

7 (21.9)

0 (0.0)

≥2x ULN

27 (73.0)

24 (75.0)

3 (60.0)

Unknown

3 (8.1)

1 (3.1)

2 (40.0)

Enolase, n (%)

<2x ULN

13 (35.1)

11 (34.3)

2 (40.0)

≥2x ULN

21 (56.8)

19 (59.4)

2 (40.0)

Unknown

3 (8.1)

2 (6.2)

1 (20.0)

LDH, n (%)

<2x ULN

9 (24.3)

8 (25.0)

1 (20.0)

≥2x ULN

28 (75.7)

24 (75.0)

4 (80.0)

PD-L1; n (%)

Positive

2 (5.4)

2 (6.2)

0 (0.0)

Negative

31 (83.8)

26 (81.3)

5 (100.0)

Unknown

4 (10.8)

4 (12.5)

0 (0.0)

MSI; n (%)

Positive

1 (2.7)

0 (0.0)

1 (20.0)

Negative

13 (35.1)

10 (31.3)

3 (60.0)

Unknown

23 (34.3)

22 (68.8)

1 (20.0)

Back to article page